Bristol-Myers Squibb Company

Bristol-Myers Squibb Company Canadian Depositary Receipt Repr Shs Reg's next confirmed earnings release is scheduled for October 29, 2026.

As of June 30, 2026, Bristol-Myers Squibb Company Canadian Depositary Receipt Repr Shs Reg has 7.81B shares outstanding.

As of June 30, 2026, Bristol-Myers Squibb Company Canadian Depositary Receipt Repr Shs Reg maintains a current ratio of 1.53, meaning it holds 1.5x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 201.86, indicating elevated leverage, while an interest coverage ratio of 8.36 demonstrates adequate ability to service its debt obligations.

Over the twelve months ended June 30, 2026, Bristol-Myers Squibb Company Canadian Depositary Receipt Repr Shs Reg posted a return on equity (ROE) of 46.70, showing how much profit the company earns on every dollar of shareholder capital. Return on invested capital (ROIC) comes in at 12.96 - the clearest signal of whether the business earns more on its capital than that capital costs, and the core measure of a durable competitive advantage. Return on assets (ROA) stands at 10.18, measuring how efficiently the asset base is converted into earnings. Return on capital employed (ROCE) is 15.67, useful for judging operating efficiency across full business cycles. The company generates approximately 2.12M in revenue per employee across its workforce of 32,900.00, a quick read on workforce productivity versus industry peers. Inventory turnover of 5.36 indicates how many times Bristol-Myers Squibb Company Canadian Depositary Receipt Repr Shs Reg sells and replaces its inventory over a year, a key working capital efficiency ratio.

Over the twelve months ended June 30, 2026, Bristol-Myers Squibb Company Canadian Depositary Receipt Repr Shs Reg recorded 3.74B in income tax expense. That works out to an effective tax rate of 22.12, which can sit above or below the statutory corporate tax rate depending on foreign earnings mix, tax credits, and one-off items. Taxes are levied on pretax income of 16.90B, leaving 13.17B in net income after tax - the gap is what shifts in the tax rate do to reported earnings and EPS.

Over the twelve months ended June 30, 2026, Bristol-Myers Squibb Company Canadian Depositary Receipt Repr Shs Reg generated 69.81B in revenue and converted that into 13.17B in net income, yielding earnings per share of 1.68. EBITDA reached 20.52B, while operating income came in at 19.64B.

As of June 30, 2026, Bristol-Myers Squibb Company Canadian Depositary Receipt Repr Shs Reg holds 15.71B in cash and equivalents against 63.94B in total debt, resulting in a net debt position of 48.82B. Total book value stands at 31.68B, with working capital of 14.08B providing operational flexibility.

Bristol-Myers Squibb Company Canadian Depositary Receipt Repr Shs Reg produced 18.14B in operating cash flow over the twelve months ended June 30, 2026.

Over the twelve months ended June 30, 2026, Bristol-Myers Squibb Company Canadian Depositary Receipt Repr Shs Reg posted a gross margin of 70.16, reflecting its pricing power and cost economics. The operating margin of 28.14 and net profit margin of 18.87 provide insight into operational efficiency.

Over the twelve months ended June 30, 2026, Bristol-Myers Squibb Company Canadian Depositary Receipt Repr Shs Reg paid dividends of 0.93 per share. The dividend payout ratio of 54.98 indicates the proportion of earnings distributed to shareholders, a key gauge of how sustainable the dividend is and how much room remains for future dividend growth.